Range
17.57 - 18.15
Vol / Avg.
128.7K/490K
Div / Yield
-
52 Wk
12.95 - 35.86
Mkt Cap
683.1M
Payout Ratio
-
Open
18.15
P/E
-
EPS
-0.55
Shares
38.2M
Outstanding
38.2M
Total Float
30.2M
Benzinga - May 13, 2021, 6:47AM
Benzinga - Apr 12, 2021, 10:15AM
Benzinga - Mar 26, 2021, 3:17PM
Benzinga - Mar 26, 2021, 3:17PM
Benzinga - Mar 26, 2021, 3:12PM
Benzinga - Mar 11, 2021, 10:45AM
Benzinga - Mar 11, 2021, 6:48AM
Benzinga - Mar 10, 2021, 4:45PM
Benzinga - Jan 19, 2021, 9:06AM
Benzinga - Jan 19, 2021, 6:26AM
Benzinga - Dec 14, 2020, 6:26AM
Benzinga - Nov 30, 2020, 10:18AM
Benzinga - Nov 12, 2020, 6:46AM
Benzinga - Nov 10, 2020, 8:17AM
load more
Sector: Health Care.Industry: Biotechnology
TCR2 Therapeutics Inc is a biotechnology company. It is engaged in developing a new generation of T cell therapies for patients suffering from cancer. Its TCR Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing the entire T cell receptor TCR signaling complex, which is effective in patients with solid tumors.

Earnings

see more
Q2 2021Est.ActualSurprise
EPS
(EXPECTED)2021-08-11
REV
Q1 2021Est.ActualSurprise
EPS-0.580
REV0

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

Related Companies

TickerCompanyChg %Mkt Cap
TCRRTCR2 Therapeutics-0.94%683.1M

TCR2 Therapeutics Frequently Asked Questions

Q

How do I buy TCR2 Therapeutics (TCRR) stock?

A

You can purchase shares of TCR2 Therapeutics (NASDAQ: TCRR) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are TCR2 Therapeutics's (TCRR) competitors?

A

Other companies in TCR2 Therapeutics’s space includes: IDEAYA Biosciences (NASDAQ:IDYA), Orchard Therapeutics (NASDAQ:ORTX), KalVista Pharmaceuticals (NASDAQ:KALV), Adaptimmune Therapeutics (NASDAQ:ADAP) and AnaptysBio (NASDAQ:ANAB).

Q

What is the target price for TCR2 Therapeutics (TCRR) stock?

A

The latest price target for TCR2 Therapeutics (NASDAQ: TCRR) was reported by SVB Leerink on March 11, 2021. The analyst firm set a price target for 34.00 expecting TCRR to rise to within 12 months (a possible 89.94% upside). 10 analyst firms have reported ratings in the last year.

Q

Current Stock Price for TCR2 Therapeutics (TCRR)?

A

The stock price for TCR2 Therapeutics (NASDAQ: TCRR) is $17.9 last updated Today at 7:04:18 PM.

Q

Does TCR2 Therapeutics (TCRR) pay a dividend?

A

There are no upcoming dividends for TCR2 Therapeutics.

Q

When is TCR2 Therapeutics (NASDAQ:TCRR) reporting earnings?

A
TCR2 Therapeutics’s Q2 earnings are confirmed for after-market on August 11, 2021.
Q

Is TCR2 Therapeutics (TCRR) going to split?

A

There is no upcoming split for TCR2 Therapeutics.

Q

What sector and industry does TCR2 Therapeutics (TCRR) operate in?

A

TCR2 Therapeutics is in the Consumer Discretionary sector and Multiline Retail industry. They are listed on the NASDAQ.